Prolonged Survival in Follicular Non Hodgkins Lymphoma is Predicted by Achievement of Complete Remission with Initial Treatment: Results of a Long Term Study with Multivariate Analysis of Prognostic Factors

References

• Armitage J. O. Treatment of non-Hodgkin's lymphoma. New England Journal of Medicine 1993; 328: 1023–1030
   PubMed Web of Science ®Google Scholar
• Straus D. J., Filippa D. A., Lieberman P. H., Koziner B., Thaler H. T., Clarkson B. D. The non-Hodgkin's Lymphomas: I. A retrospective clinical and pathologic analysis of 499 cases diagnosed between 1958–1969. Cancer 1983; 51: 101–109
   PubMed Web of Science ®Google Scholar
• The Non-Hodgkin's lymphoma pathologic classification project: National Cancer Institute sponsored study of classifications of Non-Hodgkin's lymphomas: Summary and description of a working formulation for clinical usage. Cancer 1982; 49: 2112–2135
   PubMed Web of Science ®Google Scholar
• Medeiros J., Van Krieken J. H., Jaffe E. S., Raffeld M. Association of bcl-1 rearrangements with lymphocytic lymphoma of intermediate differentiation. Blood 1990; 76: 2086–2090
   PubMed Web of Science ®Google Scholar
• Hockenberry D., Nunez G., Millman C., Schreiber R. D., Korsmeyer S. J. bcl-2 is an inner mitochondria) membrane protein that blocks programmed cell death. Nature 1990; 348: 334
   PubMed Web of Science ®Google Scholar
• Lo Coco F., Gaidano G., Louie D. C., Offik K., Chaganti R. S. K., Dalla-Favera R. p53 mutations are associated with histologic transformation of follicular lymphoma. Blood 1993; 82: 2289–2295
   PubMed Web of Science ®Google Scholar
• Baron B. W., Nucifora G., McCabe N., Espinosa R., 3rd, Le Beau M. M., McKeithan T. W. Identification of the gene associated with the recurring chromosomal translocations t(3:14) (q27;q32) and t(3;22)(q27;q11) in B-cell lymphomas. Proceedings of National Academy of Sciences of United States of America 1993; 90: 5262–5266
   PubMed Web of Science ®Google Scholar
• Jaffe E. S., Raffeld M., Medeiros L. J., Stetler-Stevenson M. An overview of the classification of non-Hodgkin's lymhomas: an integration of morphological and phenotypical concepts. Cancer Research 1992; 52: 5447, Suppl)
   PubMed Web of Science ®Google Scholar
• Croce C. M. Molecular biology of lymphomas. Seminars in Oncology 1993; 20: 31–47
   PubMed Web of Science ®Google Scholar
• Asenberg A. C. Utility of gene rearrangements in lymphoid malignancies. Annual Review of Medicine 1993; 44: 75–84
   PubMed Web of Science ®Google Scholar
• Carbone A., Pinto A., Gloghini A., Volpe R., Zagonel V. B-zone small lymphocytic lymphoma: a morphologic, immunophenotypic, and clinical study with comparison to ‘well-differentiated’ lymhocytic disorder. Human Pathology 1992; 23: 438–448
   PubMed Web of Science ®Google Scholar
• Rosenberg S. A. The low grade non-Hodgkin's lymphomas: challenges and opportunities. Journal of Clinical Oncology 1985; 3: 299–310
   PubMed Web of Science ®Google Scholar
• Portlock C. S. The role of treatment deferral in the management of patients with advanced indolent non-Hodgkin's lymphomas. Seminars in Hematology 1983; 20: 25–34
   PubMed Web of Science ®Google Scholar
• Portlock C. S., Rosenberg S. A. No initial therapy for Stage III and IV non-Hodgkin's lymphomas of favourable histologic types. Annual Internal Medicine 1979; 90: 10–13
   PubMed Web of Science ®Google Scholar
• Young R. C., Longo D. L., Glatstein E., Ihde D. C., Jaffe E. S., DeVita V. T., Jr. The treatment of indolent lymphomas: Watchful waiting versus aggressive combined modality treatment. Seminars in Hematology 1988; 25: 11–16
   PubMed Web of Science ®Google Scholar
• Chen M. G., Proznitz L. R., Gonzales-Serva A., Fischer D. B. Results of radiotherapy in control of stage I and II non-Hodgkin's lymphoma. Career 1979; 43: 1245–1254
   Google Scholar
• Gallagher C. T., Gregory W. M., Jones A. E., Stanfeld A. G., Richards M. A., Dhaliwal H. S., Malpas J. S., Lister T. A. Follicular lymphoma: prognostic factors for response and survival. Journal of Clinical Oncology 1986; 4: 1470–1480
   PubMed Web of Science ®Google Scholar
• Gomez G. A., Barcos M., Krishnamsetty R. M. Treatment of early—stage I and II—nodular poorly differentiated lymphocytic lymphoma. American Journal of Clinical Oncology 1986; 9: 40
   PubMed Web of Science ®Google Scholar
• Longo D. Cancer: Principles and Practice of Oncology, V. T. De Vita, S. Hellman, S. A. Rosenberg. Toronto: J. B. Lippincott Co, Philadelphia 1989
   Google Scholar
• Hoppe R. T., Kushlan P., Kaplan H. S., Rosenhurg S. A., Brown B. W. The treatment of advanced stage favourable histology non-Hodgkin's lymphoma: a preliminary report of a randomised trial comparing single agent chemotherapy, combination chemotherapy and whole body irradiation. Blood 1981; 58: 592–589
   PubMed Web of Science ®Google Scholar
• Paryani S. B., Hoppe R. T., Cox R. S. Analysis of non-Hodgkin's lymphomas with nodular and favourable histologies Stages I and II. Cancer 1983; 52: 2300–2307
   PubMed Web of Science ®Google Scholar
• Portlock C. S., Fischer D., Cadman E., Lundburg W. B., Levy A., Bobrow S., Bertino J. R., Farber L. High-pulse chlorambucil in advanced, low-grade non-Hodgkin's lymphomas. Cancer Treatment Reports 1978; 71: 1029–1031
   Google Scholar
• Sutcliffe S. B., Gospodarowicz M. K., Bush R. A. Role of radiation therapy in localised non-Hodgkin's lymphoma. Radiotherapy and Oncology 1985; 4: 211–223
   PubMed Web of Science ®Google Scholar
• Cavallin-Stahl E., Moller T. R. Prednimustine, Cyclophosphamidevincristine-Prednisolone in the treatment of non-Hodgkin's lymphoma with favourable histology:. results of a national cancer care pogram in Sweden. Semininar in Oncology 1986; 13: 19–22, with the Swedish Lymphoma Group.
   PubMed Web of Science ®Google Scholar
• Longo D. L., Young R. C., Hubbard S. M., Wesley M., Fisher I., Jaffe E., Berard C., DeVita V. T. Prolonged initial remission in patients with nodular mixed lymphomas. Annals in Internal Medicine 1984; 100: 651–656
   PubMed Web of Science ®Google Scholar
• Portlock C. S., Rosenberg S. A., Glatstein E., Kaplan H. S. Treatment of advanced non-Hodgkin's lymphomas with favourable histologies: preliminary results of a prospective trial. Blood 1976; 47: 747–756
   PubMed Web of Science ®Google Scholar
• Rudders R. A., Kaddis M., De Lellis R. A., Casey H., Jr. Nodular non-Hodgkin's lymphoma. Factors influencing prognosis and indications for aggressive treatment. Cancer 1979; 43: 1643–1651
   PubMed Web of Science ®Google Scholar
• Ezdinli E. Z., Anderson J. R., Melvin F., Glick J. H., Davis T. E., O'Connell M. J. Moderate versus aggressive chemotherapy of nodular lymphocytic poorly-differentiated lymphoma. Journal of Clinical Oncology 1985; 3: 769–775
   PubMed Web of Science ®Google Scholar
• Anderson T., Bender R. A., Fischer R. I., DeVita V. T., Chabner B. A., Berard C. W., Norton L., Young R. C. Combination chemotherapy in non-Hodgkin's lymphoma: results of long term follow-up. Cancer Treatment Reports 1977; 61: 1057–1066
   PubMedGoogle Scholar
• Bittran J. C., Golombick H. M., Ultmann J. E., Sweet K. L, Lester E. P., Stein R. S., Miller J. B., Morgan E. M., Kinnealey A. E., Vardiman J. E., Kinzie J., Roth N. O. Non-Hodgkin's lymphoma, poorly differentiated and mixed cell types: results of sequential staging procedures, response to therapy and survey of 100 patients. Cancer 1978; 42: 88–95
   PubMed Web of Science ®Google Scholar
• Glick J. H., Barnes J. M., Ezdinli E. Z., Berard C. W., Ordow E. L., Bennett J. M. A randomised trial failing to confirm prolonged disease free survival with COPP chemotherapy. Blood 1981; 58: 920–925
   PubMed Web of Science ®Google Scholar
• Oken M. M., Costello W. G., Johnson G. J., Lenhard R. E., Ezdinli E. Z., Orlow E., Barnes J. M., Berand C. W., Glick J. H. The influence of histologic subype on toxicity and response to chemotherapy in non-Hodgkin's lymphoma. Cancer 1983; 51: 1581–1586
   PubMed Web of Science ®Google Scholar
• Lepage E., Sebban D., Gisselbrecht C. Treatment of low-grade non-Hodgkin's lymphomas assessment of Doxorubicin in a controlled trial. Hematologic Oncology 1990; 8: 31–38
   PubMed Web of Science ®Google Scholar
• Metier G. E., Nathwani B. M., Burk J. S. Morpologic subclassification of follicular lymphoma: Variability of diagnosis among hematopathologists, a collaborative study between the repository centre and pathology panel for clinical lymphoma studies. Journal of Clinical Oncology 1985; 3: 25–38
   PubMed Web of Science ®Google Scholar
• Gospodarowicz M. G., Bush R. S., Brown T. C., Chua T. Prognostic factors in nodular lymphomas: a multivariate analysis based on the Princess Margaret Hospital experience. International Journal of Radiology Oncology and Biology Physics 1984; 10: 489–497
   PubMed Web of Science ®Google Scholar
• Qazi R., Aisenberg A. C., Long C. J. The natural history of nodular lymphoma. Cancer 1976; 37: 1923–1927
   PubMed Web of Science ®Google Scholar
• Cabanillas F., Smith T., Bodey C. P., Gutterman J. U., Freireich E. J. Nodular malignant lymphomas: factors affecting complete response and survival. Cancer 1979; 44: 1983–1989
   PubMed Web of Science ®Google Scholar
• Bastion Y., Berger F., Bryon P. P., Felman P., Ffrench M., Coiffier B. Follicular lymphomas: assessment of prognostic factors in 127 patients followed for 10 years. Annals in Oncology 1991; 2: 123–129, (Supp 2)
   PubMed Web of Science ®Google Scholar
• Romaguera J. E., McLauglin P., North L., Dixon D., Silvermintz K. B., Garnsey L. A., Velasquez W. S., Hagemeister F. B., Cabanillas F. Multivariate analysis of prognostic factors in stage IV follicular low-grade lymphomas: a risk model. Journal of Clinical Oncology 1991; 9: 9762–9769
   Google Scholar
• McLauglin P., Fuller L. M., Velasquez W. S., Sullivan-Halley J. A., Butler J. J., Cabanillas F. Stage I–II follicular lymphoma: treatment results of 76 patients. Cancer 1986; 58: 1596–1602
   PubMed Web of Science ®Google Scholar
• Warnke R. A., Kim H., Fuks Z., Dorfman R. F. The co-existence of nodular and diffuse patterns in nodular non-Hodgkin's lymphomas: Significance and clinicopathologic correlation. Cancer 1977; 40: 1229–1233
   PubMed Web of Science ®Google Scholar
• Bennet J. M., Cain K. C., Glick J. H. The significance of bone marrow involvement in non-Hodgkin's lymphoma: The Eastern co-operative Oncology Group experience. Journal of Clinical Oncology 1986; 4: 1462–1469
   PubMed Web of Science ®Google Scholar
• Gallagher C. J., Gregory W. M., Jones A. E., Stanfeld A. G., Richards M. A., Dhaliwal H. S., Malpas J. S., Lister T. A. Follicular lymphoma: prognostic factors for response and survival. Journal of Clinical Oncology 1986; 4: 1470–1480
   PubMed Web of Science ®Google Scholar
• Anderson T., De Vita V. T., Simon R. M., Berard C. W., Canellos G. P., Garvin A. J., Young R. C. Malignant lymphoma II. Prognostic factors and response to treatment of 473 patients at the National Cancer Institute. Cancer 1982; 50: 2708–2721
   PubMed Web of Science ®Google Scholar
• Steward W. P., Crowther D., McWilliam L. J., Jones J. M., Deakin D. P., Todd I. D. H., Blackledge G., Wagstaff J., Scarffe J. H., Hams M. Maintainance chlorambucil after CVP in the management of advanced stage, low-grade histologic type non-Hodgkin's lymphoma. Cancer 1988; 61: 441–447
   PubMed Web of Science ®Google Scholar
• Diggs C. H., Wiernik P. M., Ostrow S. S. Nodular lymphoma. Prolongation of survival by complete remission. Cancer Clinical Trials 1981; 4: 107–114
   PubMedGoogle Scholar